[go: up one dir, main page]

WO2005102326A3 - Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales - Google Patents

Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales Download PDF

Info

Publication number
WO2005102326A3
WO2005102326A3 PCT/IB2005/001370 IB2005001370W WO2005102326A3 WO 2005102326 A3 WO2005102326 A3 WO 2005102326A3 IB 2005001370 W IB2005001370 W IB 2005001370W WO 2005102326 A3 WO2005102326 A3 WO 2005102326A3
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
gene
transcription factor
renal diseases
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001370
Other languages
English (en)
Other versions
WO2005102326A2 (fr
Inventor
Alain Moussy
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of WO2005102326A2 publication Critical patent/WO2005102326A2/fr
Publication of WO2005102326A3 publication Critical patent/WO2005102326A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur une méthode de prévention ou de traitement de maladies rénales et des dysfonctionnements, cette méthode consistant à administrer un composé capable d'épuiser les mastocytes ou un composé inhibant la dégranulation des mastocytes. Ces composés peuvent être choisis à partir des inhibiteurs de c-kit et plus particulièrement d'inhibiteurs de c-kit non toxiques, sélectifs et puissants. De préférence, cet inhibiteur est capable de favoriser la mort des cellules dépendant d'IL-3 et mises en culture en présence d'IL-3.
PCT/IB2005/001370 2004-04-23 2005-04-19 Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales Ceased WO2005102326A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56458604P 2004-04-23 2004-04-23
US60/564,586 2004-04-23

Publications (2)

Publication Number Publication Date
WO2005102326A2 WO2005102326A2 (fr) 2005-11-03
WO2005102326A3 true WO2005102326A3 (fr) 2006-03-30

Family

ID=34967717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001370 Ceased WO2005102326A2 (fr) 2004-04-23 2005-04-19 Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales

Country Status (1)

Country Link
WO (1) WO2005102326A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080019213A (ko) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
MX2009012613A (es) 2007-05-22 2010-04-21 Achillion Pharmaceuticals Inc Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
EP2303841A1 (fr) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Composés inhibiteurs de l oxindolyle
WO2010009155A2 (fr) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Composés inhibiteurs hétérocycliques condensés
WO2010009139A2 (fr) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Composés inhibiteurs de pyrimidine imidazolyle
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
EP2440519A1 (fr) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Composés inhibiteurs d'hdac à base d'alkanoylamino benzamide aniline
AU2010259042A1 (en) 2009-06-08 2011-12-15 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015172746A1 (fr) * 2014-05-16 2015-11-19 Wellhead Biological Technology Corp. Utilisation de ginsénoside m1 pour inhiber la fibrose rénale
ES2704059T3 (es) * 2014-11-03 2019-03-14 Lee Sheau Long Uso de ginsenósido M1 para el tratamiento de nefropatía por IgA
ES3029140T3 (en) 2020-04-24 2025-06-23 Bayer Ag Substituted aminothiazoles as dgkzeta inhibitors for immune activation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03184914A (ja) * 1989-09-27 1991-08-12 Otsuka Pharmaceut Factory Inc 抗活性酸素剤
EP1205478A1 (fr) * 1999-08-06 2002-05-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
WO2003002109A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase destines a traiter des maladies auto-immunes
WO2003003006A2 (fr) * 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
WO2003004467A2 (fr) * 2001-07-06 2003-01-16 Agouron Pharmaceuticals, Inc. Derives de benzamide de thiazole et compositions pharmaceutiques inhibant la proliferation cellulaire, et methodes d'utilisation
WO2004014903A1 (fr) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit
WO2004096225A2 (fr) * 2003-04-28 2004-11-11 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de l'ischemie cerebrale

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03184914A (ja) * 1989-09-27 1991-08-12 Otsuka Pharmaceut Factory Inc 抗活性酸素剤
EP1205478A1 (fr) * 1999-08-06 2002-05-15 Takeda Chemical Industries, Ltd. INHIBITEURS DE p38MAP KINASE
WO2003002109A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase destines a traiter des maladies auto-immunes
WO2003003006A2 (fr) * 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
WO2003004467A2 (fr) * 2001-07-06 2003-01-16 Agouron Pharmaceuticals, Inc. Derives de benzamide de thiazole et compositions pharmaceutiques inhibant la proliferation cellulaire, et methodes d'utilisation
WO2004014903A1 (fr) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit
WO2004096225A2 (fr) * 2003-04-28 2004-11-11 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de l'ischemie cerebrale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199138, Derwent World Patents Index; Class B03, AN 1991-278282, XP002336319 *

Also Published As

Publication number Publication date
WO2005102326A2 (fr) 2005-11-03

Similar Documents

Publication Publication Date Title
WO2005102326A3 (fr) Utilisation d'inhibiteurs de c-kit dans le traitement des maladies renales
DK1934345T3 (da) Modifikationer af rna, der fører til en forøget transkriptstabilitet og translationseffektivitet
WO2005059096A3 (fr) Methodes pour une production haute fidelite de molecules d'acide nucleique long associee a un controle d'erreurs
WO2004024757A3 (fr) Molecules pna modifiées
WO2005123736A8 (fr) Nouveaux 2-benzylaminodihydropteridinones, procede de production associe et leur utilisation en tant que medicaments
WO2006007207A3 (fr) Procedes et dispositifs pour la determination de sequence d'acides nucleiques
WO2006135684A3 (fr) Methodes et kits pour la synthese d'arn sens
WO2006131928A3 (fr) Nouvelles sequences de nucleotides et d'acides amines, leurs dosages et methodes d'utilisation en vue du diagnostic
WO2005059097A3 (fr) Procedes de production a fidelite elevee de longues molecules d'acide nucleique
ATE538127T1 (de) 6-disubstituierte bicyclische nukleinsäureanaloga
WO2006127899A3 (fr) Synthese de (r)-n-methylnaltrexone
WO2005030984A3 (fr) Procede de synthese de petites quantites d'acides nucleiques
WO2004092418A3 (fr) Amplification globale effectuee avec une amorce composite amorcee de maniere aleatoire
WO2007117438A3 (fr) Méthodes de production d'une protéine fonctionnelle à partir d'un adn présentant une mutation non-sens et traitement des troubles associés
WO2009014612A3 (fr) Nucléotides modifiés, procédés pour les préparer et les utiliser
WO2009124255A8 (fr) Procédés pour l'analyse de produit de transcription
WO2010027497A3 (fr) Préparations, compositions et procédés de séquençage d'acides nucléiques
WO2006127287A3 (fr) Inhibiteurs a base de pyrrolopyridine, pour inhiber la dipeptidyl peptidase iv, et procedes correspondants
WO2007039903A3 (fr) Nouveaux nucleotides et nouvelles sequences d'acides amines, et bioessais et procedes d'utilisation associes a des fins de diagnostic
WO2005001039A3 (fr) Production de petits arn interferents (arnsi) regulee par les ribozymes et procedes d'utilisation de ceux-ci
WO2008139153A3 (fr) Système d'expression
WO2005076743A3 (fr) Molecules de disaccharide et leurs derives et procedes d'utilisation associes
WO2007115929A8 (fr) Thiazolyl-dihydro-quinazolines
WO2007034487A8 (fr) Constructions d’acide nucléique, compositions pharmaceutiques et procédés utilisant ces dernières dans le cadre des traitements anticancéreux
WO2006079057A3 (fr) Methodes et compositions pour une inhibition specifique d'un epissage proteinique, par de petites molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase